Zhenhua Li
Hebei Medical University(CN)Fourth Hospital of Hebei Medical University(CN)
Publications by Year
Research Areas
Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes, Esophageal and GI Pathology, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma(2022)28 cited
- → Epigenetic Study of Esophageal Carcinoma Based on Methylation, Gene Integration and Weighted Correlation Network Analysis(2021)24 cited
- → The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma(2023)21 cited
- → Pathologic lymph node ratio is a predictor of esophageal carcinoma patient survival: a literature-based pooled analysis(2017)16 cited
- → Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma(2024)11 cited
- → Comparison of Up-Front Minimally Invasive Esophagectomy versus Open Esophagectomy on Quality of Life for Esophageal Squamous Cell Cancer(2021)6 cited
- → Comparisons of minimally invasive esophagectomy and open esophagectomy in lymph node metastasis/dissection for thoracic esophageal cancer(2022)5 cited
- → Knockdown of circ_0006225 overcomes resistance to cisplatin and suppresses growth in lung cancer by miR‐1236‐3p/ANKRD22 axis(2024)4 cited
- → LncRNA U731166 Increases the Accumulation of TGFBR1 by Sponging miR-3607-3p in Esophageal Squamous-Cell Carcinomas (ESCC) to Promote Tumor Metastasis.(2024)3 cited
- → 557 Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC)(2021)2 cited